A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- Registration Number
- NCT06012240
- Lead Sponsor
- AbbVie
- Brief Summary
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA.
Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1 or Study 2, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 240 sites worldwide.
Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1500
- Adult individuals must be < 64 years old at Baseline Visit. Where permitted outside United States (US)/European Union (EU), adolescent individuals who are at least 12 years old at Screening may participate.
- Diagnosis of severe alopecia areata (AA) with Severity of Alopecia Tool (SALT) score >= 50 scalp hair loss at Screening and Baseline.
- Severe AA with no spontaneous scalp hair regrowth over the past 6 months.
- Current episode of AA of less than 8 years.
- Current diagnosis of primarily diffuse type of AA.
- Current diagnosis of other types of alopecia that would interfere with evaluation of AA, including but not limited to female pattern hair loss, male pattern hair loss (androgenetic alopecia) Stage III or greater based on Hamilton-Norwood classification, traction alopecia, lichen planopilaris (LPP), discoid lupus, frontal fibrosing alopecia (FFA), central centrifugal cicatricial alopecia (CCCA), folliculitis decalvans, trichotillomania, and telogen effluvium.
- Diagnosis of other types of inflammatory scalp, eyebrow, or eyelash disorders that would interfere with evaluation of AA as determined by the investigator, including but not limited to seborrheic dermatitis, scalp psoriasis, atopic dermatitis (AD), and tinea capitis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Study 1: Group 1 Upadacitinib Dose A Upadacitinib Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B. Study 1: Group 2 Upadacitinib Dose B Upadacitinib Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B. Study 1: Group 5 Upadacitinib Dose B Placebo Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B. Study 2: Group 3 Placebo Placebo Participants will receive matching placebo once daily for 24 weeks in Period A. Study 2: Group 5 Upadacitinib Dose B Placebo Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B. Study 1: Group 3 Placebo Placebo Participants will receive matching placebo once daily for 24 weeks in Period A. Study 1: Group 4 Upadacitinib Dose A Placebo Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B. Study 1: Group 6 Placebo Placebo Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160. Study 2: Group 2 Upadacitinib Dose B Upadacitinib Participants will receive upadacitinib Dose B once daily for 52 weeks in Period A and Period B. Study 2: Group 4 Upadacitinib Dose A Placebo Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B. Study 2: Group 5 Upadacitinib Dose B Upadacitinib Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B. Study 2: Group 6 Placebo Placebo Participants initially randomized to placebo with a SALT score ≤ 20 at Week 24 will continue on placebo through Week 160. Study 1: Group 4 Upadacitinib Dose A Upadacitinib Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B. Study 1: Group 5 Upadacitinib Dose B Upadacitinib Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose B once daily for 28 weeks in Period B. Study 2: Group 1 Upadacitinib Dose A Upadacitinib Participants will receive upadacitinib Dose A once daily for 52 weeks in Period A and Period B. Study 2: Group 4 Upadacitinib Dose A Upadacitinib Participants initially randomized to placebo (Period A) with a SALT score \> 20 at Week 24 will be re-randomized to receive upadacitinib Dose A once daily for 28 weeks in Period B. Study 3: Group 1 Upadacitinib Dose B (SALT > 20) Upadacitinib Participants receiving upadacitinib Dose A with a SALT score \> 20 at Week 52 (end of Period B) of Study 1 or Study 2 will dose escalate to upadacitinib Dose B once daily for 108 weeks. Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20) Upadacitinib Participants receiving upadacitinib Dose A with a SALT score ≤ 20 at Week 52 (end of Period B) of Study 1 or Study 2 will remain on upadacitinib Dose A once daily for 108 weeks. Study 3: Group 3 Upadacitinib Dose B (Non-Sustained) Upadacitinib Participants who end Period B on upadacitinib Dose B with a with a SALT score \> 20 at Week 40 or Week 52 of Study 1 or Study 2 will remain on upadacitinib Dose B once daily for 108 weeks. Study 3: Group 5 Upadacitinib Dose A (Sustained) Upadacitinib Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose A once daily for 108 weeks. Study 3: Group 4 Upadacitinib Dose B (Sustained) Upadacitinib Participants who end Period B on upadacitinib Dose B with a with a SALT score ≤ 20 at Week 40 and Week 52 of Study 1 or Study 2 will be re-randomized to receive upadacitinib Dose B once daily for 108 weeks.
- Primary Outcome Measures
Name Time Method Number of Participants with Adverse Events (AEs) Up to approximately 164 weeks An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 20 Week 24 The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.
- Secondary Outcome Measures
Name Time Method Achievement of SALT score <= 20 for the Comparison of Upadacitinib Dose A QD Versus Placebo Week 24 The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.
Percentage of Participants with the Achievement of Clinician-Reported Outcome (ClinRO) Measure for Eyebrow Hair Loss of 0 or 1 Baseline to Week 24 The ClinRO for Eyebrow Hair Loss is a 4-point response scale where 0 = The eyebrows have full coverage and no areas of hair loss and 3 = No notable eyebrows. Responses should have a ≥ 2-point improvement from Baseline among participants with Baseline score ≥ 2.
Percent Change from Baseline in SALT Score Baseline to Week 24 The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.
Percentage of Participants with the Achievement of Patient-Reported Outcome (PRO) for Scalp Hair Assessment 0/1 with ≥ 2-Point Improvement (Reduction) Baseline to Week 24 The PRO for Scalp Hair Assessment is single item, five-point, categorical response scale that asks respondents to look in the mirror and assess the total area of the scalp with missing hair. Response items range from "No missing hair" to "Nearly all or all" and includes percentage ranges for each category (0%, 1 to 20%, 21 to 49%, 50 to 94%, and 95 to 100%). Responses among participants with baseline score \>=3.
Achievement of Hospital Anxiety and Depression Scale (HADS)-Anxiety < 8 and HADS-Depression < 8 at Week 24 Among Participants with HADS-A >= 8 or HADS-D >= 8 at Baseline Baseline to Week 24 The HADS is a self-administered scale which measures anxiety and depression. It contains 14 items and is comprised of anxiety (7 items) and depression (7 items) subscales, which are scored separately and summed to give a total score. Item scores range from 0 (best) to 3 (worst), and total scores are categorized as normal (0 to 7), borderline abnormal (8 to 10), and abnormal (11 to 21).
Percentage of Participants with the Achievement of SALT Score <= 10 Up to Week 24 The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.
Percentage of Participants with the Achievement of ClinRO Measure for Eyelash Hair Loss of 0 or 1 Baseline to Week 24 The ClinRO for Eyelash Hair Loss is a 4-point response scale where 0 = The eyelashes form a continuous line along the eyelids on both eyes and 3 = No notable eyelashes. Responses should have a ≥ 2-point improvement from Baseline among participants with Baseline score ≥ 2.
Percentage of Participants with the Achievement of SALT Score 0 Week 24 The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.
Percentage of Participants with the Achievement of SALT 90 Baseline to Week 24 SALT 90 is defined as at least a 90% improvement \[decrease\] from Baseline in SALT score.
Percentage of Participants with the Achievement of Patients' Global Impression of Change of Alopecia Areata (PaGIC-AA) Score of 1 "Much Better" or 2 "Moderately Better" Up to Week 24 The PaGIC-AA is a single-item measure that asks participants to rate how their alopecia condition has changed overall since the start of the study using a 7-point scale. Responses range from "much better" to "much worse."
Change from Baseline in Alopecia Areata Symptom Impact Scale (AASIS) Interference Subscale Score Week 24 The AASIS Interference Subscale is a 6-item assessment with scores ranging from 0 = 'did not interfere' to 10 = 'interfered completely' with higher scores indicating greater symptom interference.
Percentage of Participants with the Achievement of SALT Score <= 20 Up to Week 12 The SALT is a global AA severity score based on the combination of extent and density of scalp hair loss. The score is determined by visually defining the amount of terminal hair loss in each of the 4 views of the scalp (left and right side each accounting for 18% of scalp area, the top for 40%, and the back for 24%) and adding these together with a maximum score of 100%.
Change from Baseline in Skindex-16 AA Emotions Domain Scores Week 24 The Skindex-16 AA Emotions Domain is a 7-item assessment ranging from 0 = never bothered to 6 = always bothered that measures the effects of AA on a subject's health-related quality of life. Higher scores indicate greater impact on health-related quality of life.
Percentage of Participants with the Achievement of SALT 75 Baseline to Week 24 SALT 75 is defined as at least a 75% improvement \[decrease\] from Baseline in SALT score.
Change from Baseline in AASIS Symptoms Subscale Score Week 24 The AASIS Symptom Subscale is a 7-item assessment with scores ranging from 0 = 'not present' to 10 = 'as bad as you can imagine' with higher scores indicating greater symptom severity.
Change from Baseline in Skindex-16 AA Functioning Domain Scores Week 24 The Skindex-16 AA Emotions Domain is a 5-item assessment ranging from 0 = never bothered to 6 = always bothered, that measures the effects of AA on a subject's health-related quality of life. Higher scores indicate greater impact on health-related quality of life.
Trial Locations
- Locations (267)
Total Skin and Beauty Dermatology Center /ID# 259539
🇺🇸Birmingham, Alabama, United States
Advanced Research Associates - Glendale /ID# 259108
🇺🇸Glendale, Arizona, United States
Southwest Skin Specialists /ID# 258234
🇺🇸Phoenix, Arizona, United States
Alliance Dermatology and Mohs Center /ID# 258111
🇺🇸Phoenix, Arizona, United States
Johnson Dermatology Clinic /ID# 259103
🇺🇸Fort Smith, Arkansas, United States
Joseph Raoof Md,Inc /Id# 258031
🇺🇸Encino, California, United States
First OC Dermatology /ID# 259220
🇺🇸Fountain Valley, California, United States
University of California Irvine /ID# 259096
🇺🇸Irvine, California, United States
Dermatology Research Associates /ID# 258033
🇺🇸Los Angeles, California, United States
Stanford University School of Medicine - Redwood City /ID# 259542
🇺🇸Redwood City, California, United States
Integrative Skin Science and Research /ID# 258114
🇺🇸Sacramento, California, United States
University of California Davis Health /ID# 258112
🇺🇸Sacramento, California, United States
Clinical Trials Research Institute /ID# 258021
🇺🇸Thousand Oaks, California, United States
Skin Care Research Boca Raton /ID# 258012
🇺🇸Boca Raton, Florida, United States
Apex Clinical Trials /ID# 259205
🇺🇸Brandon, Florida, United States
Florida Academic Dermatology Center /ID# 259353
🇺🇸Coral Gables, Florida, United States
Skin Research Institute LLC /ID# 259207
🇺🇸Coral Gables, Florida, United States
Revival Research /ID# 259213
🇺🇸Doral, Florida, United States
Skin Care Research - Hollywood /ID# 259210
🇺🇸Hollywood, Florida, United States
GSI Clinical Research, LLC /ID# 259352
🇺🇸Margate, Florida, United States
Life Clinical Trials /ID# 259358
🇺🇸Margate, Florida, United States
Lenus Research and Medical Group /ID# 259356
🇺🇸Miami, Florida, United States
International Clinical Research - Sanford /ID# 259547
🇺🇸Sanford, Florida, United States
FWD Clinical Research /ID# 266687
🇺🇸Tamarac, Florida, United States
Advanced Clinical Research Institute /ID# 259204
🇺🇸Tampa, Florida, United States
Avita Clinical Research /ID# 258011
🇺🇸Tampa, Florida, United States
Cleaver Medical Group Dermatology /ID# 259801
🇺🇸Dawsonville, Georgia, United States
Marietta Dermatology /ID# 259818
🇺🇸Marietta, Georgia, United States
Northwestern University Feinberg School of Medicine /ID# 259555
🇺🇸Chicago, Illinois, United States
NorthShore University HealthSystem - Skokie /ID# 266684
🇺🇸Skokie, Illinois, United States
Indiana University Health University Hospital /ID# 259827
🇺🇸Indianapolis, Indiana, United States
U.S. Dermatology Partners Leawood /ID# 259203
🇺🇸Leawood, Kansas, United States
Tulane University School of Medicine /ID# 259799
🇺🇸New Orleans, Louisiana, United States
Care Access /ID# 268453
🇺🇸Marriottsville, Maryland, United States
MetroBoston Clinical Partners /ID# 259559
🇺🇸Boston, Massachusetts, United States
Lahey Hospital & Medical Center /ID# 260484
🇺🇸Burlington, Massachusetts, United States
Great Lakes Research Group - Bay City /ID# 259100
🇺🇸Bay City, Michigan, United States
Hamzavi Dermatology - Canton /ID# 260115
🇺🇸Canton, Michigan, United States
Clin Res Inst of Michigan, LLC /ID# 259802
🇺🇸Chesterfield, Michigan, United States
Clarkston Dermatology /ID# 258018
🇺🇸Clarkston, Michigan, United States
Henry Ford Medical Center - New Center One /ID# 258067
🇺🇸Detroit, Michigan, United States
M Health Fairview University of Minnesota Medical Center - East Bank /ID# 260122
🇺🇸Minneapolis, Minnesota, United States
Minnesota Clinical Study Center /ID# 259218
🇺🇸New Brighton, Minnesota, United States
Dermatology and Skin Center of Lees Summit /ID# 259206
🇺🇸Lee's Summit, Missouri, United States
Physician Research Collaboration, LLC /ID# 259354
🇺🇸Lincoln, Nebraska, United States
Skin Specialists /ID# 259237
🇺🇸Omaha, Nebraska, United States
Skin Cancer and Dermatology Institute - Reno /ID# 259208
🇺🇸Reno, Nevada, United States
The Skin Center Dermatology Group /ID# 266748
🇺🇸New City, New York, United States
Schweiger Dermatology, P.C. /ID# 258007
🇺🇸New York, New York, United States
Schweiger Dermatology, P.C. /ID# 259531
🇺🇸New York, New York, United States
Equity Medical, LLC /ID# 266680
🇺🇸New York, New York, United States
Icahn School of Medicine at Mount Sinai /ID# 259808
🇺🇸New York, New York, United States
Sadick Research Group LLC /ID# 266790
🇺🇸New York, New York, United States
Piedmont Plastic Surgery and Dermatology /ID# 258206
🇺🇸Huntersville, North Carolina, United States
Cleveland Clinic - Cleveland /ID# 258113
🇺🇸Cleveland, Ohio, United States
Remington-Davis Clinical Research /ID# 258106
🇺🇸Columbus, Ohio, United States
Dermatologists of Southwest Ohio, Inc /ID# 260116
🇺🇸Mason, Ohio, United States
Dermatologist of Central States (DOCS) Clinical Research - Springfield /ID# 266746
🇺🇸Springfield, Ohio, United States
Oregon Dermatology and Research Center /ID# 258243
🇺🇸Portland, Oregon, United States
Oregon Medical Research Center /ID# 258107
🇺🇸Portland, Oregon, United States
University of Pittsburgh Medical Center /ID# 266681
🇺🇸Pittsburgh, Pennsylvania, United States
Medical University of South Carolina /ID# 259828
🇺🇸Charleston, South Carolina, United States
Health Concepts /ID# 266678
🇺🇸Rapid City, South Dakota, United States
International Clinical Research - Tennessee LLC /ID# 259552
🇺🇸Murfreesboro, Tennessee, United States
Arlington Research Center, Inc /ID# 258028
🇺🇸Arlington, Texas, United States
Bellaire Dermatology Associates /ID# 259360
🇺🇸Bellaire, Texas, United States
U.S. Dermatology Partners - Cedar Park /ID# 259367
🇺🇸Cedar Park, Texas, United States
Dermatology Treatment and Research Center /ID# 259357
🇺🇸Dallas, Texas, United States
Modern Research Associates, PLLC /ID# 259349
🇺🇸Dallas, Texas, United States
Reveal Research Institute, Dallas /ID# 259361
🇺🇸Dallas, Texas, United States
Center for Clinical Studies - Houston - Northwest Freeway /ID# 258036
🇺🇸Houston, Texas, United States
Progressive Clinical Research /ID# 259365
🇺🇸San Antonio, Texas, United States
Complete Dermatology /ID# 258025
🇺🇸Sugar Land, Texas, United States
Buenos Aires Skin /ID# 258297
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Instituto de Neumonologia y Dermatologia /ID# 258640
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Psoriahue Med Interdisciplinar /ID# 258641
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Instituto De Investigaciones Clínicas Córdoba /ID# 260244
🇦🇷Córdoba, Cordoba, Argentina
Centro de Investigacion y Prevencion Cardiovascular (CIPREC) /ID# 258639
🇦🇷Buenos Aires, Argentina
Momentum Clinical Research /ID# 258571
🇦🇺Darlinghurst, New South Wales, Australia
St George Dermatology & Skin Cancer Centre /ID# 258567
🇦🇺Kogarah, New South Wales, Australia
Cornerstone Dermatology /ID# 258769
🇦🇺Coorparoo, Queensland, Australia
Veracity Clinical Research /ID# 258566
🇦🇺Woolloongabba, Queensland, Australia
Skin Health Institute Inc /ID# 258570
🇦🇺Carlton, Victoria, Australia
Sinclair Dermatology - Melbourne /ID# 258565
🇦🇺East Melbourne, Victoria, Australia
The Royal Melbourne Hospital /ID# 258770
🇦🇺Parkville, Victoria, Australia
Fremantle Dermatology /ID# 260207
🇦🇺Fremantle, Western Australia, Australia
Universite Libre de Bruxelles - Hopital Erasme /ID# 257314
🇧🇪Anderlecht, Bruxelles-Capitale, Belgium
Universitair Ziekenhuis Brussel /ID# 257325
🇧🇪Jette, Bruxelles-Capitale, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 257320
🇧🇪Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
CHU de Liège /ID# 257316
🇧🇪Liège, Liege, Belgium
UZ Gent /ID# 257317
🇧🇪Gent, Oost-Vlaanderen, Belgium
AZ Delta - campus Torhout /ID# 257321
🇧🇪Torhout, West-Vlaanderen, Belgium
Irmandade da Santa Casa de Misericordia de Porto Alegre /ID# 258045
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Upeclin Fmb - Unesp /Id# 258046
🇧🇷Botucatu, Sao Paulo, Brazil
Hospital e Maternidade Celso Pierro - PUC-Campinas /ID# 258105
🇧🇷Campinas, Sao Paulo, Brazil
Instituto Brasil de Pesquisa Clinica S.A - IBPClin /ID# 258750
🇧🇷Rio de Janeiro, Brazil
Hospital Alemao Oswaldo Cruz /ID# 258104
🇧🇷Sao Paulo, Brazil
Diagnostic Consultative Center Aleksandrovska /ID# 257049
🇧🇬Sofiya, Sofia, Bulgaria
UMHAT Sveti Georgi /ID# 257548
🇧🇬Plovdiv, Bulgaria
Ambulatory for Specialized Medical Care for skin and venereal diseases /ID# 257047
🇧🇬Sofia, Bulgaria
Diagnostic consultative center Focus-5 /ID# 257048
🇧🇬Sofiya, Bulgaria
XX Diagnostic consultative center Sofia EOOD /ID# 257273
🇧🇬Sofiya, Bulgaria
UMHAT Professor Stoyan Kirkovich /ID# 257051
🇧🇬Stara Zagora, Bulgaria
Dermatology Research Institute - Blackfoot Trail /ID# 258818
🇨🇦Calgary, Alberta, Canada
Beacon Dermatology Inc /ID# 258817
🇨🇦Calgary, Alberta, Canada
Rejuvenation Dermatology - Edmonton Downtown /ID# 258816
🇨🇦Edmonton, Alberta, Canada
Dr. Chih-ho Hong Medical Inc. /ID# 258814
🇨🇦Surrey, British Columbia, Canada
Wiseman Dermatology Research /ID# 258819
🇨🇦Winnipeg, Manitoba, Canada
SimcoDerm Medical and Surgical Dermatology Center /ID# 258820
🇨🇦Barrie, Ontario, Canada
Leader Research /ID# 267028
🇨🇦Hamilton, Ontario, Canada
Lynde Institute for Dermatology /ID# 258815
🇨🇦Markham, Ontario, Canada
JRB Research /ID# 259248
🇨🇦Ottawa, Ontario, Canada
SKiN Centre for Dermatology /ID# 258813
🇨🇦Peterborough, Ontario, Canada
York Dermatology Clinic & Research Centre /ID# 267026
🇨🇦Richmond Hill, Ontario, Canada
Medicor Research Inc /ID# 258810
🇨🇦Sudbury, Ontario, Canada
Private Practice - Dr. Kim Papp Clinical Research /ID# 259249
🇨🇦Waterloo, Ontario, Canada
Innovaderm Research Inc. /ID# 258812
🇨🇦Montréal, Quebec, Canada
Centre de Recherche dermatologique du Quebec Metropolitain /ID# 258811
🇨🇦Québec, Quebec, Canada
Private Practice - Dr. Angelique Gagne-Henley /ID# 267027
🇨🇦St-Jérôme, Quebec, Canada
Fundacion Innovacion Cardiovascular /ID# 259313
🇨🇱Independencia, Region Metropolitana De Santiago, Chile
Centro Medico Skin Med SPA /ID# 259314
🇨🇱Las Condes, Region Metropolitana Santiago, Chile
Centro Internacional de Estudios Clinicos - CIEC /ID# 259312
🇨🇱Santiago, Region Metropolitana Santiago, Chile
Clinica Dermacross /ID# 259311
🇨🇱Vitacura, Region Metropolitana Santiago, Chile
Beijing Chaoyang Hospital,Capital Medical University /ID# 258912
🇨🇳Beijing, Beijing, China
China-Japan Friendship Hospital /ID# 258941
🇨🇳Beijing, Beijing, China
Peking University People's Hospital /ID# 258940
🇨🇳Beijing, Beijing, China
Beijing Tongren Hospital Affiliated To Capital Medical University /ID# 266715
🇨🇳Beijing, Beijing, China
The Second Affiliated Hospital of Chongqing Medical University /ID# 260254
🇨🇳Chongqing, Chongqing, China
The First Affiliated Hospital, Sun Yat-sen University /ID# 257367
🇨🇳Guangzhou, Guangdong, China
Dermatology Hospital of Southern Medical University /ID# 257118
🇨🇳Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University /ID# 258663
🇨🇳Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University /ID# 258485
🇨🇳Guangzhou, Guangdong, China
Shenzhen People's Hospital /ID# 258208
🇨🇳Shenzhen, Guangdong, China
Shenzhen Second People's Hospital /ID# 258060
🇨🇳Shenzhen, Guangdong, China
Union Hospital - Tongji Medical College /ID# 266737
🇨🇳Wuhan, Hubei, China
Renmin Hospital of Wuhan University /ID# 260260
🇨🇳Wuhan, Hubei, China
Dermatology Hospital of Jiangxi Provincial /ID# 259488
🇨🇳Nanchang, Jiangxi, China
The First Hospital of Jilin University /ID# 257496
🇨🇳Changchun, Jilin, China
Second Affiliated Hospital of Xian Jiaotong University /ID# 257497
🇨🇳Xi'an, Shaanxi, China
Dermatology Hospital Affiliated to Shandong First Medical University /ID# 267520
🇨🇳Jinan, Shandong, China
Huashan Hospital, Fudan University /ID# 257758
🇨🇳Shanghai, Shanghai, China
First Affiliated Hospital of Shanxi Medical University /ID# 259647
🇨🇳Taiyuan, Shanxi, China
Chengdu Second Municipal People's Hospital /ID# 259492
🇨🇳Chengdu, Sichuan, China
West China Hospital, Sichuan University /ID# 259560
🇨🇳Chengdu, Sichuan, China
Tianjin Medical University General Hospital /ID# 259525
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 257260
🇨🇳Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 257119
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University /ID# 257739
🇨🇳Wenzhou, Zhejiang, China
DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 257151
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicki bolnicki centar Zagreb /ID# 257630
🇭🇷Zagreb, Grad Zagreb, Croatia
Poliklinika Solmed /ID# 257651
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicki Bolnicki Centar (KBC) Split /ID# 257632
🇭🇷Split, Splitsko-dalmatinska Zupanija, Croatia
Specialty hospital Medico /ID# 257629
🇭🇷Rijeka, Croatia
Chu de Nice-Hopital Larchet Ii /Id# 256978
🇫🇷Nice, Alpes-Maritimes, France
Hopital Ponchaillou /ID# 257520
🇫🇷Rennes, Bretagne, France
Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-Andre /ID# 257519
🇫🇷Bordeaux, Gironde, France
Polyclinique Courlancy /ID# 256977
🇫🇷Reims, Marne, France
CHU de Nantes, Hotel Dieu -HME /ID# 256982
🇫🇷Nantes, Pays-de-la-Loire, France
HCL - Hopital Edouard Herriot /ID# 256983
🇫🇷Lyon, Rhone, France
CHRU de Brest - Hopital Morvan /ID# 256979
🇫🇷Brest, France
Centre de Sante Sabouraud /ID# 257213
🇫🇷Paris, France
Hôpital Charles-Nicolle /ID# 256981
🇫🇷Rouen, France
CHU Toulouse - Hopital Larrey /ID# 256980
🇫🇷Toulouse, France
Fachklinik Bad Bentheim /ID# 257741
🇩🇪Bad Bentheim, Niedersachsen, Germany
Universitaetsklinikum Duesseldorf /ID# 257307
🇩🇪Düsseldorf, Nordrhein-Westfalen, Germany
Universitaetsklinikum Muenster /ID# 257306
🇩🇪Muenster, Nordrhein-Westfalen, Germany
Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 257305
🇩🇪Lübeck, Schleswig-Holstein, Germany
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 257310
🇩🇪Berlin, Germany
Klinikum rechts der Isar /ID# 257609
🇩🇪Munich, Germany
General Hospital Andreas Syggros /ID# 257259
🇬🇷Athens, Attiki, Greece
General Hospital Andreas Syggros /ID# 257262
🇬🇷Athens, Attiki, Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 257263
🇬🇷Thessaloniki, Greece
Papageorgiou General Hospital /ID# 257258
🇬🇷Thessaloniki, Greece
Bacs-Kiskun Varmegyei Oktatokorhaz /ID# 257472
🇭🇺Kecskemet, Bacs-Kiskun, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 257468
🇭🇺Pecs, Baranya, Hungary
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 258552
🇭🇺Szeged, Csongrad, Hungary
Debreceni Egyetem-Klinikai Kozpont /ID# 257465
🇭🇺Debrecen, Hajdu-Bihar, Hungary
DERMA-B Egeszsegugyi es Szolgaltato - Debrecen - Gyepusor Utca /ID# 257469
🇭🇺Debrecen, Hungary
Bagoly Egeszseghaz (Meditres Kft.) /ID# 258032
🇭🇺Kecskemet, Hungary
The Chaim Sheba Medical Center /ID# 257770
🇮🇱Ramat Gan, Tel-Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 257771
🇮🇱Tel Aviv, Tel-Aviv, Israel
Hadassah Medical Center-Hebrew University /ID# 257946
🇮🇱Jerusalem, Yerushalayim, Israel
Rambam Health Care Campus /ID# 257769
🇮🇱Haifa, Israel
Rabin Medical Center /ID# 257772
🇮🇱Haifa, Israel
IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 257499
🇮🇹Bologna, Emilia-Romagna, Italy
AZIENDA USL TOSCANA CENTRO - Ospedale Piero Palagi /ID# 257501
🇮🇹Florence, Firenze, Italy
Presidio Ospedaliero San Salvatore /ID# 257506
🇮🇹L'Aquila, L Aquila, Italy
IRCCS Istituto Clinico Humanitas /ID# 257500
🇮🇹Rozzano, Lombardia, Italy
Azienda Ospedaliera Universitaria Federico II /ID# 257504
🇮🇹Naples, Napoli, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 258585
🇮🇹Naples, Napoli, Italy
Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 257502
🇮🇹Rome, Roma, Italy
Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 257513
🇮🇹Rome, Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 257505
🇮🇹Rome, Roma, Italy
ASST degli Spedali Civili di Brescia /ID# 257508
🇮🇹Brescia, Italy
AOU Policlinico G. Rodolico - San Marco /ID# 257507
🇮🇹Catania, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 257503
🇮🇹Milano, Italy
Kurume University Hospital /ID# 257255
🇯🇵Kurume-shi, Fukuoka, Japan
Kitasato University Hospital /ID# 257285
🇯🇵Sagamihara-shi, Kanagawa, Japan
Niigata University Medical & Dental Hospital /ID# 259425
🇯🇵Niigata-shi, Niigata, Japan
Osaka Metropolitan University Hospital /ID# 257256
🇯🇵Osaka-shi, Osaka, Japan
Hamamatsu University Hospital /ID# 257253
🇯🇵Hamamatsu-shi, Shizuoka, Japan
Tokyo Medical University Hospital /ID# 258132
🇯🇵Shinjuku-ku, Tokyo, Japan
Yamaguchi University Hospital /ID# 257252
🇯🇵Ube-shi, Yamaguchi, Japan
Kyorin University - Mitaka Campus /ID# 257283
🇯🇵Mitaka, Japan
Pusan National University Hospital /ID# 257910
🇰🇷Busan, Busan Gwang Yeogsi, Korea, Republic of
Kyungpook National University Hospital /ID# 257908
🇰🇷중구, Daegu Gwang Yeogsi, Korea, Republic of
Chungnam National University Hospital /ID# 267151
🇰🇷Daejeon, Daejeon Gwang Yeogsi, Korea, Republic of
Chungang University Hospital /ID# 267155
🇰🇷Dongjak-gu, Gyeonggido, Korea, Republic of
Seoul National University Bundang Hospital /ID# 257906
🇰🇷Seongnam-si, Gyeonggido, Korea, Republic of
Inha University Hospital /ID# 257904
🇰🇷Incheon, Incheon Gwang Yeogsi, Korea, Republic of
Jeonbuk National University Hospital /ID# 267154
🇰🇷Jeonju, Jeonrabugdo, Korea, Republic of
Seoul National University Hospital /ID# 257903
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Konkuk University Medical Center /ID# 257900
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Kyung Hee University Hospital at Gangdong /ID# 257907
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Hallym University Kangdong Sacred Heart Hospital /ID# 257905
🇰🇷Seoul, Korea, Republic of
Greenlane Clinical Centre /ID# 258563
🇳🇿Epsom, Auckland, New Zealand
Clinical Trials New Zealand /ID# 258564
🇳🇿Hamilton, Waikato, New Zealand
Aotearoa Clinical Trials /ID# 258562
🇳🇿Auckland, New Zealand
P3 Research Ltd /ID# 259846
🇳🇿Wellington, New Zealand
Dermodent Centrum Medyczne Aldona Czajkowska Rafał Czajkowski /ID# 258242
🇵🇱Osielsko, Kujawsko-pomorskie, Poland
MICS Centrum Medyczne Torun /ID# 257740
🇵🇱Torun, Kujawsko-pomorskie, Poland
Specjalistyczny Gabinet Dermatologiczny Aplikacyjno Badawczy /ID# 257534
🇵🇱Krakow, Malopolskie, Poland
Royalderm Agnieszka Nawrocka /ID# 257536
🇵🇱Warsaw, Mazowieckie, Poland
Klinika Osipowicz & Turkowski sp.z.o.o /ID# 257598
🇵🇱Warszawa, Mazowieckie, Poland
Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 257531
🇵🇱Bialystok, Podlaskie, Poland
Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 257535
🇵🇱Gdansk, Pomorskie, Poland
Centrum Medyczne Angelius Provita /ID# 257916
🇵🇱Katowice, Slaskie, Poland
Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 257537
🇵🇱Elblag, Warminsko-mazurskie, Poland
Centrum Medyczne ALL-MED Badania Kliniczne /ID# 257590
🇵🇱Cracow, Poland
Unidade Local de Saude de Almada-Seixal, EPE /ID# 257425
🇵🇹Almada, Portugal
Hospital CUF Descobertas /ID# 257419
🇵🇹Lisboa, Portugal
Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 258554
🇵🇹Porto, Portugal
Santa Cruz Behavioral (SCB) Research Center /ID# 259350
🇵🇷Bayamon, Puerto Rico
Dr. Samuel Sanchez PSC /ID# 259359
🇵🇷Caguas, Puerto Rico
Clinical Research Puerto Rico /ID# 259355
🇵🇷San Juan, Puerto Rico
GCM Medical Group PSC /ID# 258013
🇵🇷San Juan, Puerto Rico
Mindful Medical Research /ID# 260113
🇵🇷San Juan, Puerto Rico
Derma therapy spol /ID# 257595
🇸🇰Bratislava, Bratislavsky Kraj, Slovakia
Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 257593
🇸🇰Presov, Presovsky Kraj, Slovakia
Univerzitna nemocnica Bratislava, Nemocnica Stare mesto /ID# 257594
🇸🇰Bratislava, Slovakia
Kaderma Majtan s.r.o. /ID# 257596
🇸🇰Topolcany, Slovakia
Hospital Universitari de Bellvitge /ID# 257332
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Reina Sofia /ID# 257035
🇪🇸Córdoba, Cordoba, Spain
Hospital Universitario de Fuenlabrada /ID# 257334
🇪🇸Fuenlabrada, Madrid, Spain
Hospital Santa Creu i Sant Pau /ID# 257034
🇪🇸Barcelona, Spain
Hospital Universitario La Paz /ID# 257333
🇪🇸Madrid, Spain
Hospital Universitario Dr. Peset /ID# 257036
🇪🇸Valencia, Spain
Karolinska University Hospital Solna /ID# 257094
🇸🇪Solna, Stockholms Lan, Sweden
Diagnostiskt Centrum Hud /ID# 257229
🇸🇪Stockholm, Stockholms Lan, Sweden
CTC GoCo /ID# 257714
🇸🇪Mölndal, Vastra Gotalands Lan, Sweden
Kaohsiung Chang Gung Memorial Hospital /ID# 258726
🇨🇳Kaohsiung City, Kaohsiung, Taiwan
National Taiwan University Hospital /ID# 257407
🇨🇳Taipei City, Taipei, Taiwan
National Cheng Kung University Hospital /ID# 257409
🇨🇳Tainan, Taiwan
Taipei Veterans General Hosp /ID# 257413
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 258725
🇨🇳Taoyuan City, Taiwan
Gulhane Egitim ve Arastirma Hastanesi /ID# 257509
🇹🇷Ankara, Turkey
Ankara City Hospital /ID# 257417
🇹🇷Ankara, Turkey
Gaziantep Universitesi /ID# 257418
🇹🇷Gaziantep, Turkey
Bagcilar Medipol Mega Universite Hastanesi /ID# 257449
🇹🇷Istanbul, Turkey
Erciyes University Medical Faculty /ID# 259034
🇹🇷Kayseri, Turkey
Velocity Clinical Research Ltd /ID# 257925
🇬🇧High Wycombe, Buckinghamshire, United Kingdom
Royal Sussex County Hospital /ID# 257912
🇬🇧Brighton, East Sussex, United Kingdom
Gloucestershire Royal Hospital /ID# 257953
🇬🇧Gloucester, Gloucestershire, United Kingdom
Chelsea and Westminster Hospital /ID# 259128
🇬🇧London, Greater London, United Kingdom
Oxford University Hospitals NHS Foundation Trust /ID# 257948
🇬🇧Oxford, Oxfordshire, United Kingdom
London North West University Healthcare NHS Trust /ID# 257914
🇬🇧Harrow, United Kingdom
Northern Care Alliance NHS Group /ID# 257952
🇬🇧Salford, United Kingdom
Related News
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis ...
- Prev
- 1
- Next